Fig. 5
From: miR-378d suppresses malignant phenotype of ESCC cells through AKT signaling
miR378d regulated AKT. a, b Differentially expressed proteins enrichment analysis. c Gene enrichment analysis of miR-378d predicting target genes. d Luciferase reporter vector design contained wild-type or mutation-type AKT1 mRNA 3′UTR (109–130 bp). e Dual-luciferase activity assay; miR-378d (20 nM) reduced the luciferase activity of WT-AKT1-3′UTR but not that of Mut-AKT1-3′UTR. f, g Western blot analysis detected the protein expression levels of p-AKT and AKT1; GAPDH served as an internal reference. h, i Western blot assay detected the expression levels of β-catenin, E-cadherin, ALDH1A1, and Vimentin. GAPDH served as an internal reference. j Western blot assay detected the protein expression levels of AKT, β-catenin, ALDH1A1, and Vimentin after miR-378d inhibition and MK2206 or XAV939 treatment in ESCC cells